


IN THE CLAIMS:

1. (Currently amended) A compound comprising ~~Compounds of the formula I~~



wherein in which

- R^1 , $R^{1'}$, R^2 each, independently of one another, are selected from the group consisting of ~~stand for~~ Hal, A, OH, OA, SA, SO₂H, SO₂A, SO₃H, SO₃A, CN, NO₂, NH₂, NHA, NAA', NHCOA, CHO, C(=O)A, COOH, COOA, CONH₂, CONHA and ~~or~~ CONAA',
- L is selected from the group consisting of ~~denotes~~ CH₂, CH₂CH₂, O, S, SO, SO₂, NH, NA, C=O or CHOH,
- R^2 , ~~independently, is selected from the meanings indicated for R^1 and $R^{1'}$ and is preferably, independently, selected from Hal, A, OH, OA, CN, COOH, COOA, CONH₂, CONHA or CONAA';~~
- E, G, M,
- Q and U each, independently of one another, are selected from the group consisting of ~~stand for~~ a C atom and ~~or~~ an N atom,
- A, A', independently of one another, are selected from unsubstituted or substituted alkyl having 1-10 C atoms, unsubstituted or substituted cycloalkyl having 3-10 C atoms, unsubstituted or substituted alkoxyalkyl having 2-12 C atoms, unsubstituted or substituted aryl having 6-14 C atoms, unsubstituted or substituted arylalkyl having 7-15 C atoms, unsubstituted or substituted, saturated, unsaturated or aromatic heterocyclyl having 2-7 C atoms and 1-3 hetero atoms selected from the group consisting of N, O and S, or unsubstituted or substituted, saturated, unsaturated or aromatic heterocyclylalkyl

having 3-10 C atoms and 1-3 hetero atoms selected from the group consisting of N, O and S,

Hal is selected from the group consisting of F, Cl, Br and I, and

m, p, q each, independently of one another, are ~~denote~~ 0, 1, 2, 3 or 4, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

2. (Currently amended) The compound ~~Compounds~~ according to Claim 1, wherein in which in which the radicals

R¹, independently of one another, is ~~are~~ selected from the group consisting of A, Hal, CN, COOH, COOA, SO₂A, C(=O)A, NH₂, NHA and NO₂, and

m is ~~denotes~~ 1, 2 or 3, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

3. (Currently amended) The compound ~~Compounds~~ according to Claim 1 wherein in which the radicals

R¹, independently of one another, is ~~are~~ selected from the group consisting of methyl, ethyl, CF₃, OCF₃, F, Cl, Br, CN, COOH, COOCH₃, COOCH₂CH₃, SO₂CH₃, NH₂, NHCH₃, NHCH₂CH₃, NO₂, and thiophen-2-ylcarbonyl, and

m is ~~denotes~~ 1, 2 or 3, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

4. (Currently amended) The compound ~~Compounds~~ according to claim 1 wherein one or more of Claims 1-3 in which

R^{1'} is ~~denotes~~ Hal or A,

p is ~~denotes~~ 0 or 1,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

5. (Currently amended) The compound ~~Compounds~~ according to claim 1 wherein one or more of Claims 1-4 in which

L is selected from the group consisting of ~~denotes~~ O, S and ~~or~~ CH₂, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

6. (Currently amended) The compound ~~Compounds~~ according to claim 1 wherein one or more of Claims 1-5 in which

R² is selected from the group consisting of ~~denotes~~ A, COOA, CONHA and ~~or~~ CONH₂, and

q is ~~denotes~~ 0, 1 or 2, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

7. (Currently amended) The compound ~~Compounds~~ according to claim 1 wherein one or more of Claims 1-6 in which

R¹, independently of one another, is selected from the group consisting of ~~denotes~~ Hal, alkyl, CN, COOH, COOalkyl, SO₂alkyl, NH₂, NHalkyl, C(=O)alkyl, C(=O)heterocyclyl and ~~or~~ NO₂,

m is ~~denotes~~ 1, 2 or 3, preferably 1 or 2,

R^{1'} is ~~denotes~~ Hal or A, preferably Hal or alkyl,


p is ~~denotes~~ 0 or 1,

L is selected from the group consisting of ~~denotes~~ O, S and ~~or~~ CH₂, preferably O or CH₂,


R² is selected from the group consisting of ~~denotes~~ A, COOalkyl, CONHalkyl and ~~or~~ CONH₂, and

q is ~~denotes~~ 0, 1 or 2, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

8. (Currently amended) The compound ~~Compounds~~ according to claim 1 wherein one or more of Claims 1-7 in which
the group



in formula I is selected from the group consisting of



wherein ~~in which~~ L, R² and q have the meanings indicated in claim 1 ~~one or more of Claims 1 to 7~~,
and pharmaceutically usable derivatives, solvates and stereoisomers thereof,
including mixtures thereof in all ratios.


9. (Currently amended) The compound ~~Compounds~~ according to claim 1 ~~one of Claims 1 to 8~~, selected from the group consisting of
- (5-chloro-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)-phenyl]amine;
 - [4-(pyridin-4-yloxy)phenyl](6-trifluoromethyl-1H-benzimidazol-2-yl)-amine;
 - (6-methyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
 - (5-chloro-4-methyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]-amine;
 - (4-bromo-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)-phenyl]amine;
 - (4-bromo-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)-phenyl]amine;
 - (5,6-dimethyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
 - (5-chloro-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)-phenyl]amine;
 - (5,6-dichloro-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
 - (5,6-dichloro-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
 - (5-chloro-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;

(5-chloro-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
 (4-methyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
 (4-chloro-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)-
 phenyl]amine;
 (4-chloro-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)-
 phenyl]amine;
 (4,5-dimethyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
 (5-chloro-6-methyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]-
 amine;
 (5-chloro-6-methyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]-
 amine;
 (4,6-bistrifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]-
 amine;
 (4,6-bistrifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]-
 amine;
 [4-(pyridin-3-yloxy)phenyl](6-trifluoromethyl-1H-benzimidazol-2-yl)-
 amine;
 (6-methyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
 (4,5-dimethyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
 (5-chloro-4-methyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]-
 amine;
 (4-methyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
 (5,6-dimethyl-1H-benzimidazol-2-yl)[4-(pyridin-3-yloxy)phenyl]amine;
 (4-bromo-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(2,6-dimethyl-
 pyrimidin-4-yloxy)phenyl]amine;
 N-methyl-4-[4-(bromotrifluoromethyl-1H-benzimidazol-2-ylamino)-
 phenoxy]pyridine-2-carboxamide;
 2-[4-(pyridin-4-yloxy)phenylamino]-3H-benzimidazole-5-carbonitrile;

[4-(2-amino-6-methylpyrimidin-4-yloxy)phenyl](4-bromo-6-trifluoromethyl-1H-benzimidazol-2-yl)amine;
 (4-chloro-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(2,6-dimethylpyrimidin-4-yloxy)phenyl]amine;
 [4-(2-amino-6-methylpyrimidin-4-yloxy)phenyl](4-chloro-6-trifluoromethyl-1H-benzimidazol-2-yl)amine;
 (6-nitro-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
 methyl 2-[4-(pyridin-4-yloxy)phenylamino]-3H-benzimidazole-5-carboxylate;
 2-[4-(pyridin-4-yloxy)phenylamino]-3H-benzimidazole-5-carboxylic acid;
 methyl 7-methanesulfonyl-2-[4-(pyridin-4-yloxy)phenylamino]-3H-benzimidazole-5-carboxylate;
 (4-fluoro-6-trifluoromethyl-1H-benzimidazol-2-yl)[4-(pyridin-4-yloxy)phenyl]amine;
 [4-(2,6-dimethylpyrimidin-4-yloxy)phenyl](4-fluoro-6-trifluoromethyl-1H-benzimidazol-2-yl)amine;
 [4-(2-amino-6-methylpyrimidin-4-yloxy)phenyl](4-fluoro-6-trifluoromethyl-1H-benzimidazol-2-yl)amine;
 N-methyl-4-{4-[6-(1-thiophen-2-ylmethanoyl)-1H-benzimidazol-2-ylamino]phenoxy}pyridine-2-carboxamide; and
 N²-[4-(pyridin-4-yloxy)phenyl]-3H-benzimidazole-2,5-diamine;
 and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.


10. (Currently amended) A process ~~Process~~ for the preparation of compounds of the formula I ~~according to Claims 1-9~~ and pharmaceutically usable derivatives, solvates and stereoisomers thereof, comprising reacting characterised in that

a compound of the formula II



~~wherein in which~~ R^1 and m have the meanings indicated in Claim 1,

~~is reacted~~ with a compound of the formula III



~~wherein in which~~ R^1 , L, E, G, M, Q, U, R^2 and q have the meanings indicated in Claim 1,

and optionally converting the compound of formula I into a salt.

~~if desired the compound of the formula I is isolated, and/or a base or acid of the formula I is converted into one of its salts.~~

11. (Currently amended) A pharmaceutical composition ~~Medicaments~~ comprising at least one compound according to claim 1 ~~one of Claims 1 to 9~~ and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients or ~~and/or~~ adjuvants.
12. (Currently amended) A method of treatment of diseases comprising inhibiting, regulating or modulating kinase signal transduction comprising

administering to a patient in need thereof, a pharmaceutical composition according to claim 11.

13. (Currently amended) The method Use according to Claim 12, wherein said
~~where the~~ kinases are selected from the group consisting of tyrosine kinases
and Raf kinases.
14. (Currently amended) The method Use according to Claim 13, wherein said
~~where the~~ tyrosine kinases are TIE-2.
15. (Canceled).
16. (Canceled).
17. (Currently amended) The method Use according to Claim 12 wherein said
~~15 or 16, where the~~ disease comprises ~~to be treated~~ is a solid tumour.
18. (Currently amended) The method Use according to Claim 17 wherein said
~~17, where the~~ solid tumour originates from the group consisting of brain
tumour, tumour of the urogenital tract, tumour of the lymphatic system,
stomach tumour, laryngeal tumour and lung tumour.
19. (Currently amended) The method Use according to Claim 17, wherein said
~~where the~~ solid tumour originates from the group consisting of monocytic
leukaemia, lung adenocarcinoma, small cell lung carcinomas, pancreatic
cancer, glioblastomas and breast carcinoma.
20. (Currently amended) The method Use according to Claim 12 wherein
angiogenesis is implicated in said disease 15 or 16 for the treatment of a
~~disease in which angiogenesis is implicated.~~
21. (Currently amended) The method Use according to Claim 20, wherein said
~~where the~~ disease is an ocular disease.

22. (Currently amended) The method Use according to Claim 12 wherein said disease is selected from the group consisting of 15 or 16 for the treatment of retinal vascularisation, diabetic retinopathy, age-induced macular degeneration and ~~and/or~~ inflammatory diseases.
23. (Currently amended) The method Use according to Claim 22, wherein said ~~where the~~ inflammatory disease originates from the group consisting of rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reaction.
24. (Currently amended) The method Use according to Claim 12 wherein said disease involves 15 or 16 for the treatment of bone pathologies, wherein ~~said where the~~ bone pathology originates from the group consisting of osteosarcoma, osteoarthritis and rickets.
25. (Currently amended) The pharmaceutical composition according to claim 11 comprising at least one additional Medicaments comprising at least one compound according to Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
26. (Currently amended) A kit comprising Set (kit) consisting of separate packs of
 - (a) an effective amount of a compound according to Claim 1 or ~~and/or~~ pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and
 - (b) an effective amount of an additional ~~a further medicament~~ active ingredient.

27. (Currently amended) The method according to claim 12 wherein said pharmaceutical composition ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumours, where a therapeutically effective amount of a compound according to one of Claims 1 to 9 is~~ administered in combination with a compound from the group consisting of 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) a prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) another angiogenesis inhibitor.
28. (Currently amended) The method according to claim 12 wherein said pharmaceutical composition ~~Use of compounds according to one of Claims 1 to 9 or and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumours where a therapeutically effective amount of a compound according to one of Claims 1 to 9 is~~ administered in combination with radiotherapy and a compound from the group consisting of 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) another angiogenesis inhibitor.
29. (Currently amended) The method according to claim 12 wherein said pharmaceutical composition ~~Use according to Claim 12, 13 or 14, for the preparation of a medicament for the treatment of diseases which are based on disturbed TIE-2 activity, where a therapeutically effective amount of a compound according to one of Claims 1 to 9 is~~ administered in combination with a growth-factor receptor inhibitor.

30. (Currently amended) The method according to claim 12 wherein said diseases Use according to Claim 12 or 13 of compounds according to Claim 1, and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,

for the preparation of a medicament for the treatment of diseases which are caused, mediated or and/or propagated by Raf kinases.
31. (Currently amended) The method Use according to Claim 30, wherein said where the Raf kinase is selected from the group consisting of A-Raf, B-Raf and Raf-1.
32. (Currently amended) The method Use according to Claim 12 wherein said 30, where the diseases are selected from the group consisting of the hyperproliferative and non-hyperproliferative diseases.
33. (Currently amended) The method according to claim 12 wherein said Use according to Claim 30 or 32, where the disease is cancerous.
34. (Currently amended) The method according to claim 12 wherein said Use according to Claim 30 or 32, where the disease is non-cancerous.
35. (Currently amended) The method according to claim 34 wherein said Use according to Claim 30, 32 or 34, where the non-cancerous diseases are selected from the group consisting of psoriasis, arthritis, inflammation, endometriosis, scarring, benign prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases.
36. (Currently amended) The method according to claim 33 wherein said cancerous Use according to one of Claims 30, 32 or 33, where the diseases are selected from the group consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic

cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.